Thrombus and antiplatelet therapy in type 2 diabetes mellitus: A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina

Girish N. Viswanathan, Sally M. Marshall, Clyde B. Schechter, Karthik Balasubramaniam, José J. Badimon, Azfar G. Zaman

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Type 2 diabetes mellitus (T2DM) is associated with higher rates of thrombotic complications in patients with coronary artery disease (CAD) despite optimal medical therapy. Thrombus area was measured in T2DM and non-diabetic patients receiving aspirin and clopidogrel 7-10 days after troponin positive Non ST-elevation acute coronary syndrome (NSTE-ACS). Secondly, we assessed response to clopidogrel in naive patients with T2DM and stable CAD in a randomised controlled trial. Thrombus area was measured by Badimon chamber and platelet reactivity by VerifyNow®. In T2DM patients presenting with NSTE-ACS, thrombus area was greater compared to non-diabetic patients (mean ± SD, 20,512 ± 12,567 [n=40] vs. 14,769 ± 8,531 [n=40] μm2/mm, p=0.02) Clopidogrel decreased thrombus area among stable CAD patients with T2DM (mean ± SD, Clopidogrel [n=45]: 13,978 ± 5,502 to 11,192 ± 3,764 μm 2/mm vs. placebo [n=45]: 13,959 ± 7,038 to 14,201 ± 6,780 μm 2/mm, p<0.001, delta values: clopidogrel vs. placebo, mean ± SD, 2,786 ± 4,561 vs. -249 ± 2,478, p<0.0005). Only 44% of patients with CAD and T2DM responded to clopidogrel as per VerifyNow® (cutoff PRUz value of ≥240). Importantly, no correlation was observed between thrombus area and VerifyNow® values (rho 0.08, p=0.49). Thrombus area values were similar among hypo-responders and good responders to clopidogrel (mean thrombus area ± SD: 12,186 ± 4,294 vs. 10,438 ± 3,401; p=0.17). Type 2 diabetes mellitus is associated with an increased blood thrombogenicity among NSTE-ACS patients on currently recommended medical therapy. Thrombus area was significantly reduced in all stable CAD patients independently of their response to clopidogrel therapy.

Original languageEnglish (US)
Pages (from-to)937-945
Number of pages9
JournalThrombosis and Haemostasis
Volume108
Issue number5
DOIs
StatePublished - Sep 1 2012

Keywords

  • Acute coronary syndrome
  • Antiplatelet therapy
  • Stable coronary artery disease
  • Thrombus
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Thrombus and antiplatelet therapy in type 2 diabetes mellitus: A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina'. Together they form a unique fingerprint.

  • Cite this